BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 100.9% from a year ago
Cash & equivalents stood at $52.66M at the end of Q1 FY2026, up 100.9% from a year earlier and down 85.9% from the prior quarter.
Context
- Cash & equivalents amounted to 12.6% of total assets at the end of Q1 FY2026, down 4.9 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +100.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 373.69M USD
- Year-over-year change
- +21910.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 373.69M | +21910.4% |
| FY2024 | 2024-12-31 | 1.7M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cash & Equivalents vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +100.9% is the 3rd highest of 10, against a peer median of +7.5%.
- Cash & equivalents amounts to 12.6% of total assets for BBOT, versus a peer median of 42.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M USD | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $248.47M USD | +151.9% | +49.5% | 75.4% | |
| Mar 2026 | $180.9M USD | -14.8% | -5.8% | 59.3% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M USD | -47.8% | +58.0% | 27.0% |
| Mar 2026 | $111.3M USD | +7.0% | +26.0% | 43.9% | |
| Sep 2026 | $88.68M USD | +23.1% | +3.3% | 42.3% | |
| Sep 2026 | $86.84M USD | +48.8% | +23.3% | 8.4% | |
| Mar 2026 | CHF 64.37M CHF | +7.5% | +60.2% | 26.5% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $52.66M USD | +100.9% | — | 12.6% |
| Jun 2026 | $44.66M USD | +0.5% | +0.1% | 6.2% | |
| Peer median (excluding BBOT) | — | +7.5% | +26.0% | 42.3% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.